Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) announced that Emil D. Kakkis, M.D., Ph.D., CEO and president, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT. A live webcast and archived replay will be available via the company investor website at https://ir.ultragenyx.com/events-presentations. The webcast replay will remain accessible for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
In the Jan 8 session, RARE declined 4.09%, reflecting a moderate negative market reaction. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | BLA submission | Positive | +1.0% | Completed DTX401 BLA submission to FDA supported by Phase 3 data. |
| Dec 29 | Phase 3 results | Negative | -42.3% | Setrusumab Phase 3 trials missed primary fracture-rate endpoints. |
| Dec 19 | Inducement grants | Neutral | +3.7% | Granted 13,144 RSUs to new non-executive officers under inducement plan. |
| Nov 24 | Investor conferences | Neutral | +2.3% | Participation in Citi and Evercore ISI healthcare investor conferences. |
| Nov 21 | Inducement grants | Neutral | -2.4% | Granted 18,180 RSUs to newly hired non-executive officers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Price reactions have generally aligned with news tone, with a sharp selloff on negative Phase 3 data and modest moves on regulatory and routine corporate updates.
Over the last few months, Ultragenyx reported mixed clinical and corporate developments. A Dec 29, 2025 Phase 3 setback for setrusumab drove a -42.32% move, while completion of the DTX401 BLA on Dec 30, 2025 saw a modest +0.97% reaction. Inducement grants in November and December and participation in investor conferences produced smaller, directionally consistent moves, indicating trading that generally tracks the perceived importance of each event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 AM PT.
The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
